Early Results of Clinical Application of Autologous Whole Bone Marrow Stem Cell Transplantation for Critical Limb Ischemia with Buerger's Disease

Seon-Hee Heo, Yoong-Seok Park, Eun-Suk Kang, Kwang-Bo Park, Young-Soo Do, Kyung-Sun Kang, Dong-Ik Kim, Seon-Hee Heo, Yoong-Seok Park, Eun-Suk Kang, Kwang-Bo Park, Young-Soo Do, Kyung-Sun Kang, Dong-Ik Kim

Abstract

Our goal was to evaluate early results of the clinical application of autologous whole bone marrow stem cell transplantation (AWBMSCT) for critical limb ischemia (CLI) in patients with Buerger's disease. We retrospectively analyzed the data of 58 limbs of 37 patients (mean age, 43.0 years; range, 28-63 years; male, 91.9%) with Buerger's disease with CLI who were treated with AWBMSCT from March 2013 to December 2014. We analyzed Rutherford category, pain score, pain-free walking time (PFWT), total walking time (TWT), ankle brachial pressure index (ABPI), and toe brachial pressure index (TBPI), and investigated wound healing and occurrence of unplanned amputations. The mean follow-up duration was 11.9 ± 7.2 months (range, 0.9-23.9 months) and 100%, 72.4%, and 74.1% of patients were available to follow-up 1, 3 and 6 months after AWBMST, respectively. At 6 months, patients demonstrated significant improvements in Rutherford category (P < 0.0001), pain score (P < 0.0001), PFWT (P < 0.0001) and TBPI (P < 0.0001). ABPI was increased compared to baseline, but the difference was not significant. A total of 76.5% ischemic wounds achieved complete or improved healing. AWBMSCT is a safe and effective alternative or adjunctive treatment modality to achieve clinical improvement in patients with CLI.

Figures

Figure 1
Figure 1
Serial changes in Rutherford category (0–6) (A) and CLI-free ratio (B) after AWBMSCT (n = 58 at 1 month, n = 42 at 3 months, n = 43 at 6 months). *Represents P < 0.05 compared with baseline data.
Figure 2
Figure 2
Serial changes in pain score (numeric rating scale, NRS) (A) and pain-free walking time (PFWT)(sec) (B) after AWBMSCT (n = 58 at 1 month, n = 42 at 3 months, n = 43 at 6 months). *Represents P < 0.05 compared with data at baseline, †Represents P < 0.05 compared with data at 1 month after treatment, ‡Represents P < 0.05 compared with data at 3 months after treatment.
Figure 3
Figure 3
Serial changes in ankle brachial pressure index (ABPI) (A) and toe brachial pressure index (TBPI) (B) after AWBMSCT (n = 58 at 1 month, n = 42 at 3 months, n = 43 at 6 months). *Represents P < 0.05 compared with data at baseline, †Represents P < 0.05 compared with data at 1 month after treatment, ‡Represents P < 0.05 compared with data at 3 months after treatment.

References

    1. Rutherford R. B. et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J. Vasc. Surg. 26, 517–538 (1997).
    1. Norgren L. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur. J. Vasc. Endovasc. Surg. 33 Suppl 1, S1–75 (2007).
    1. Klein-Weigel P. F. & Richter J. G. Thromboangiitis obliterans (Buerger’s disease). Vasa 43, 337–346 (2014).
    1. Paraskevas K. I., Liapis C. D., Briana D. D. & Mikhailidis D. P. Thromboangiitis obliterans (Buerger’s disease): searching for a therapeutic strategy. Angiology 58, 75–84 (2007).
    1. Kim A. K. et al. Stem-cell therapy for peripheral arterial occlusive disease. Eur. J. Vasc. Endovasc. Surg. 42, 667–675 (2011).
    1. Kim D. I. et al. Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger’s disease. Stem Cells 24, 1194–1200 (2006).
    1. Lee K. B. et al. Stem cell therapy in patients with thromboangiitis obliterans: assessment of the long-term clinical outcome and analysis of the prognostic factors. Int. J. Stem Cells 4, 88–98 (2011).
    1. Giles K. A., Rzucidlo E. M., Goodney P. P., Walsh D. B. & Powell R. J. Bone marrow aspirate injection for treatment of critical limb ischemia with comparison to patients undergoing high-risk bypass grafts. J. Vasc. Surg. 61, 134–137 (2015).
    1. Teraa M. et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann. Surg. 258, 922–929 (2013).
    1. Shionoya S. Diagnostic criteria of Buerger’s disease. Int. J. Cardiol. 66 Suppl 1, S243–245; discussion S247 (1998).
    1. Botti C., Maione C., Coppola A., Sica V. & Cobellis G. Autologous bone marrow cell therapy for peripheral arterial disease. Stem Cells Cloning 5, 5–14 (2012).
    1. Botham C. M., Bennett W. L. & Cooke J. P. Clinical trials of adult stem cell therapy for peripheral artery disease. Methodist Debakey Cardiovasc. J. 9, 201–205 (2013).
    1. Tateishi-Yuyama E. et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360, 427–435 (2002).
    1. Prochazka V. et al. Autologous bone marrow stem cell transplantation in patients with end-stage chronical critical limb ischemia and diabetic foot. Vnitr. Lek. 55, 173–178 (2009).
    1. Motukuru V., Suresh K. R., Vivekanand V., Raj S. & Girija K. R. Therapeutic angiogenesis in Buerger’s disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J. Vasc. Surg. 48, 53S–60S; discussion 60S (2008).
    1. Matoba S. et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am. Heart J. 156, 1010–1018 (2008).
    1. Iafrati M. D. et al. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J. Vasc. Surg. 54, 1650–1658 (2011).
    1. Amann B. et al. Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI). Vasa 37, 319–325 (2008).
    1. Durdu S. et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J. Vasc. Surg. 44, 732–739 (2006).
    1. Huang P. P. et al. Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thromb. Haemost. 91, 606–609 (2004).
    1. Amann B., Luedemann C., Ratei R. & Schmidt-Lucke J. A. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 18, 371–380 (2009).

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다